{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:38:59Z","timestamp":1784738339029,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cpcardiol.2024.102615","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T15:26:05Z","timestamp":1714404365000},"page":"102615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-6461","authenticated-orcid":false,"given":"Konstantinos","family":"Pamporis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Sagris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippokratis","family":"Zarifis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Bougioukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Pagkalidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikias","family":"Milaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Xanthos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Giannakoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102615_bib0001","article-title":"Global Burden of Cardiovascular Diseases and Risks, 1990-2022","volume":"82","author":"George","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: a systematic review","volume":"108","author":"Emmons-Bell","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","article-title":"Economic Issues in Heart Failure in the United States: A Report from the Heart Failure Society of America","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0004","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0005","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101867","article-title":"Comparison of international guidelines for managing chronic heart failure with reduced ejection fraction","volume":"48","author":"Nabil","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0008","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ehf2.14206","article-title":"Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020","volume":"10","author":"\u00d8degaard","year":"2023","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0012","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0013","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0014","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and\/or Chronic Kidney Disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.amjcard.2023.04.038","article-title":"A Systematic Review and Meta-Analysis on Effectiveness of Mineralocorticoid Receptor Antagonists in Reducing the Risk of Atrial Fibrillation","volume":"199","author":"Fatima","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0017","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)","author":"Higgins","year":"2022","journal-title":"Cochrane"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0018","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0019","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0020","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"PW","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0021","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0022","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae185","article-title":"Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction","author":"Schupp","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1145\/2110363.2110464","article-title":"Deploying an interactive machine learning system in an Evidence-based Practice Center: Abstrackr. IHI\u201912 - Proc 2nd","author":"Wallace","year":"2012","journal-title":"ACM SIGHIT Int Heal Informatics Symp"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0024","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0028","first-page":"105","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF","volume":"77","author":"Naser","year":"2023","journal-title":"Med Arch (Sarajevo, Bosnia Herzegovina)"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0029","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jrsm.1301","article-title":"A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data","volume":"9","author":"Watkins","year":"2018","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11121-021-01289-6","article-title":"Network Meta-Analysis Techniques for Synthesizing Prevention Science Evidence","volume":"23","author":"Seitidis","year":"2022","journal-title":"Prev Sci"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0031","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0032","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0034","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ahj.2018.07.002","article-title":"A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial","volume":"204","author":"Korol","year":"2018","journal-title":"Am Hear J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0035","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0036","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0037","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0038","article-title":"Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction","volume":"10","author":"Kocaba\u015f","year":"2023","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0039","article-title":"Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum","volume":"10","author":"Chen","year":"2023","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0041","article-title":"Patient eligibility for established and novel guideline-directed medical therapies after acute heart failure hospitalization","author":"M","year":"2023","journal-title":"Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0042","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jval.2012.01.004","article-title":"Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure","volume":"15","author":"McKenna","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0043","doi-asserted-by":"crossref","unstructured":"Abuelazm M, Badr A, Turkmani M, et al. The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis. ESC Hear Fail 2023. https:\/\/doi.org\/10.1002\/EHF2.14588.","DOI":"10.1002\/ehf2.14588"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0044","article-title":"Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use","author":"Clark","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0045","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0046","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril\/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0047","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142023","volume":"46","author":"Elsayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0048","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0049","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/dom.14883","article-title":"Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use","volume":"25","author":"Rossing","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0051","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0052","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","article-title":"Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials","volume":"24","author":"Yang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0053","article-title":"Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102615_bib0054","doi-asserted-by":"crossref","first-page":"E294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624002548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624002548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:12:03Z","timestamp":1716948723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624002548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0146280624002548"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102615","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102615"}}